Technical Analysis for HTBX - Heat Biologics, Inc.

Grade Last Price % Change Price Change
grade F 1.35 -2.17% -0.03
HTBX closed down 2.17 percent on Wednesday, January 16, 2019, on 1.5 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
7 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Flat Up
See historical HTBX trend table...

Date Alert Name Type % Chg
Jan 16 Fell Below 50 DMA Bearish 0.00%
Jan 16 Calm After Storm Range Contraction 0.00%
Jan 16 Weak + Overbought Other 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 16 Overbought Stochastic Strength 0.00%
Jan 15 50 DMA Support Bullish -2.17%
Jan 15 MACD Bullish Centerline Cross Bullish -2.17%
Jan 15 Wide Bands Range Expansion -2.17%
Jan 15 Overbought Stochastic Strength -2.17%
Jan 15 Upper Bollinger Band Touch Strength -2.17%

Older signals for HTBX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Is HTBX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 14 UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Jan 14 Dosing underway in expanded lung cancer study of Heat Biologics' HS-110
Jan 14 Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Jan 10 The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
Jan 10 Heat Biologics expands mid-stage study of HS-110 to include different PD-1 inhibitor
Jan 10 Heat Biologics Provides Clinical and Business Update
Jan 8 Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Jan 7 Israel's Anchiano Therapeutics files for American-share IPO
Jan 4 Heat Biologics to Present at Biotech Showcase 2019 in California
Dec 27 The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
See more HTBX news...
Indicators
Indicator Value
52 Week High 4.3
52 Week Low 0.95
Average Volume 444,567
200-Day Moving Average 1.7666
50-Day Moving Average 1.3517
20-Day Moving Average 1.1453
10-Day Moving Average 1.25
Average True Range 0.1097
ADX 31.55
+DI 29.4244
-DI 16.3288
Chandelier Exit (Long, 3 ATRs ) 1.1609
Chandelier Exit (Short, 3 ATRs ) 1.2791
Upper Bollinger Band 1.4309
Lower Bollinger Band 0.8597
Percent B (%b) 0.86
BandWidth 49.873396
MACD Line 0.0097
MACD Signal Line -0.0414
MACD Histogram 0.0511
Fundamentals Value
Market Cap 48.31 Million
Num Shares 35.8 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -3.14
Price-to-Sales 26.16
Price-to-Book 2.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.57
Resistance 3 (R3) 1.57 1.50 1.53
Resistance 2 (R2) 1.50 1.44 1.50 1.52
Resistance 1 (R1) 1.42 1.41 1.39 1.42 1.51
Pivot Point 1.35 1.35 1.33 1.35 1.35
Support 1 (S1) 1.28 1.30 1.24 1.28 1.19
Support 2 (S2) 1.21 1.26 1.21 1.18
Support 3 (S3) 1.13 1.21 1.17
Support 4 (S4) 1.13